GSK extends agreement with Peakdale for discovery research
Under the extension of the agreement through 2005, GSK continues to make use of Peakdale's synthetic chemistry abilities, and have expanded the agreement to include support for GSK's Cardiovascular and Urogenital (CVU) CEDD.
Kim Morrison, Peakdale CEO, commented, "Peakdale is known for its abilities to devise new synthetic routes to challenging compounds in a flexible and responsive service, delivering on time and in full. This revised agreement gives GSK continuation of a dedicated team of chemists for the duration of the projects."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.